Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 64
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 15
Results: 15
1
2
Novel Perioperative Combinations Show Efficacy in Resectable NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 63
- By:
- Publication type:
- Article
3
Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 60
- By:
- Publication type:
- Article
4
Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 58
- By:
- Publication type:
- Article
5
Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 52
- By:
- Publication type:
- Article
6
Education, Telehealth, and Access Initiatives Aim to Improve Cancer Care for Veterans.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 48
- By:
- Publication type:
- Article
7
THE MICROBIOME AND COLON CANCER: Dietary Influence on Incidence, Morbidity, and Mortality.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 46
- By:
- Publication type:
- Article
8
First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 43
- By:
- Publication type:
- Article
9
Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 36
- By:
- Publication type:
- Article
10
An Era of Firsts in CML: Asciminib Challenges SOC TKIs.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 30
- By:
- Publication type:
- Article
11
Obe-Cel May Expand CAR T-Cell Therapy Options in Relapsed/Refractory ALL.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 22
- By:
- Publication type:
- Article
12
Adjuvant Ribociclib Expands Access to CDK4/6 Inhibition in High-Risk HR+/HER2-- Breast Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 14
- By:
- Publication type:
- Article
13
FDA Digest.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 12
- Publication type:
- Article
14
CANCER CLINICAL TRIALS: A Relevant Need to Clearly Define the Value to Individual Patients.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 10
- By:
- Publication type:
- Article
15
New Research Aims to Improve Cancer Care in All Sectors.
- Published in:
- OncologyLive, 2024, v. 25, n. 15, p. 8
- By:
- Publication type:
- Article